Author: ["Klaus W Wagner","Elizabeth A Punnoose","Thomas Januario","David A Lawrence","Robert M Pitti","Kate Lancaster","Dori Lee","Melissa von Goetz","Sharon Fong Yee","Klara Totpal","Ling Huw","Viswanatham Katta","Guy Cavet","Sarah G Hymowitz","Lukas Amler","Avi Ashkenazi"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Apo2L/TRAIL stimulates cancer cell death through the proapoptotic receptors DR4 and DR5, but the determinants of tumor susceptibility to this ligand are not fully defined. mRNA expression of the peptidyl O-glycosyltransferase GALNT14 correlated with Apo2L/TRAIL sensitivity in pancreatic carcinoma, non–small-cell lung carcinoma and melanoma cell lines, and up to 30% of samples from various human malignancies showed GALNT14 overexpression. RNA interference of GALNT14 reduced cellular Apo2L/TRAIL sensitivity, whereas overexpression increased responsiveness. Biochemical analysis of DR5 identified several ectodomain O-(N-acetyl galactosamine–galactose–sialic acid) structures. Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling. O-glycosylation promoted ligand-stimulated clustering of DR4 and DR5, which mediated recruitment and activation of the apoptosis-initiating protease caspase-8. These results uncover a new link between death-receptor O-glycosylation and apoptotic signaling, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.Cite this article
Wagner, K., Punnoose, E., Januario, T. et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13, 1070–1077 (2007). https://doi.org/10.1038/nm1627 